70 likes | 80 Views
The major drivers for the biobanking market include the need for cost-effective drug discovery and development, rising prevalence of chronic diseases, increasing funding, and surging genomic research activities.
E N D
The global biobanking market is expected to generate $36.8 billion revenue by 2024, advancing at a CAGR of 6.2%, during the forecast period. Factors, such as increasing need for cost-effective drug discovery, and rising demand for cell lines, directly pose a positive impact on the market growth. Explore report at: https://www.psmarketresearch.com/market-analysis/biobanking-market “
Based on offering, the biobanking market is classified into consumables, equipment, services, and software. Of these, the consumables category is expected to lead the market in the coming years. Further, the market in the software category is predicted to advance at a CAGR of 5.4%, during the forecast period. The consumables category is further bifurcated into storage, analysis, processing, and collection. Out of all the consumables, the consumables utilized for storage is expected to dominate the overall biobanking market in the future, mainly due to the increasing number of blood products, tissues, and cell lines being preserved in the biobanks.
The biobanking market in APAC is expected to witness lucrative growth as a consequence of increasing awareness about biobanking in the region, witnessing a CAGR of 6.8% during the forecast period. Growing population, and increasing clinical research are the other factors that positively impact the growth of the market in this region. Further, due to the growing research activities, there is a wide scope for the growth of the biotechnology sector in this region. This growth is also likely to be supported by the large amount of funds that are received from various government and private sectors organizations. Presence of regional players also contribute to the growth of the market. Request for report sample at: https://www.psmarketresearch.com/market-analysis/biobanking-market/report-sample
The biobanking market is categorized into blood products and genetic materials, human tissues, cell lines, biological fluids, and human waste products, based on the type of sample. Amongst these, the blood products and genetic material category is expected to hold the largest revenue share during the forecast period, with a contribution of 42.1% by 2024 in the global market. Dur to the rising prevalence of chronic diseases, it is expected that preservation of blood products such as plasma, serum, and platelets would be on rise in the coming future. Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biobanking-market
The biobanking market is fragmented in nature; Thermo Fisher Scientific Inc, Merck KGaA, Promega Corporation, Becton, Dickinson and Company, Hamilton Company, Avantor Inc., Tecan Group Ltd., QIAGEN N.V., PHC Holdings Corporation, Brooks Automation Inc., AutoGen Inc., BioCision, BioLife Solutions Inc. are some of the major players with a broad presence in this market. Similarly, in March 2019, Becton, Dickinson and Company launched automated flow cytometry sample preparation instrument with CE-IVD certification known as, BD FACSDuet. This instrument helps in understanding the characteristics of cell as well as counting.
THANK YOU! For queries, kindly write to: enquiry@psmarketresearch.com GET IN TOUCH www.psmarketresearch.com B-13, Sector-2, Noida, U.P.-201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 US/Canada Toll-Free: 1-888-778-7886